Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Similac Probiotic Triblend
- Development stage
- Discontinued
- Lead developer
- Abbott
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Similac Probiotic Tri-Blend is a multi-strain probiotic supplement developed by Abbott Laboratories in collaboration with Chr. Hansen. It was specifically designed for use in neonatal intensive care units (NICUs) for preterm and very-low-birth-weight (VLBW) infants. The product contains live bacterial strains, including *Bifidobacterium infantis* (Bb-02) and *Streptococcus thermophilus* (TH-4), intended to promote healthy gut microbiome development and reduce the incidence of necrotizing enterocolitis (NEC). In October 2023, the FDA issued a warning letter classifying the product as an unapproved new drug and unlicensed biological product, citing safety concerns regarding its use in preterm infants. Consequently, Abbott discontinued sales and initiated a voluntary recall in November 2023.
- Brand names
- Similac Probiotic TriblendSimilac Probiotic Tri-Blend
- Other names
- Bifidobacterium infantis (Bb-02) + Streptococcus thermophilus (TH-4)
Beyond the preview
Go deeper on Similac Probiotic Triblend.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Similac Probiotic Triblend.